Name: Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (sdAb-Fc-sdAb)
SKU: HCAB-036
Rating: 5 (1 reviews)

Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (sdAb-Fc-sdAb, Tetravalent Heavy Chain-only Antibody, Tetravalent HCAb) is symmetric protein with two pairs of single domain antibodies (sdAb), from anti-CD64 and anti-EGFR antibodies, fused to the N-terminus and C-terminus of the Fc separately. This BsAb is bispecific, tetravelant, 2+2 antigen-binding valency. It can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD64 & EGFR

Type

sdAb-Fc-sdAb

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors

Host Animal 1

llama

Host Animal 2

llama

Targets

Target 1

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Target 2

EGFR

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (sdAb-Fc-sdAb) (HCAB-036). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (sdAb-Fc-sdAb) (CAT#: HCAB-036)

Specifications

Targets

Customer Reviews and Q&As